Loading
Loading…
Loading…
Ref. No.
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
| # | Schedule | Awardee / L1 Bidder | Status | Bids | Value |
|---|---|---|---|---|---|
| 1 | Schedule 1 | - | Evaluation in Progress | - | - |
| 2 | Schedule 2 | JVB MEDICARE PRIVATE LIMITED | Awarded | 1 | ₹47,970 |
| 3 | Schedule 3 | SAI KRISHNA AGENCIES | Awarded | 1 | ₹3.5 L |
| 4 | Schedule 4 | JAI GANESH PHARMACEUTICALS | Awarded | 1 | ₹36,036 |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
29 Jul 2025, 8:00 pmClosed
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
TAB ESOMEPRAZOLE 40 MG
TAB SEVELAMER 400 MG
TAB LEMBOREXANT 5MG
TAB EVEROLIMUS 0.25 MG
8025523
GEM/2025/B/6396366
Two Packet Bid
TAB ESOMEPRAZOLE 40 MG
30 days
Visakhapatnam
Item wise evaluation
PRODUCT_CUSTOM
7 documents required · 7 mandatory
3 yrs
₹4 L
₹4 L
50%
Exempted
30 Jul 2025
8 Jul 2025
29 Jul 2025
TAB ESOMEPRAZOLE 40 MG
TAB SEVELAMER 400 MG
TAB LEMBOREXANT 5MG
TAB EVEROLIMUS 0.25 MG
TAB EVEROLIMUS 0.25 MG
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_8025523.pdf
GEM_BID
specification2_2025-06-30-00-08-58_43d93e72ec383423b9b062dd2c5f2977.pdf
SPECIFICATION
specification2_2025-06-30-00-10-04_754a5785a391c43b9278e08bba33cb65.pdf
SPECIFICATION
specification2_2025-06-30-00-10-59_37702fe9d354a7fa89f4be0e263cba0a.pdf
SPECIFICATION
specification2_2025-06-30-00-11-54_4990c3e70a6f793df7994cfd718e19c2.pdf
SPECIFICATION
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .